Using Accelerometer-Based Portable Navigation to Perform Accurate Total Knee Arthroplasty Bone Resection in Asian Patients

February 27, 2017- Hideki Ueyama, MD ; Yoshio Matsui, MD , PhD; Yukihide Minoda, MD , PhD; Masanori Matsuu ra, MD ; Hiroaki Nakamura, MD , PhD Total knee arthroplasty (TKA) is one of the most successful surgeries for patients with degenerative joint dis­ease, and many studies have shown good results from TKA.1-3 Implant alignment … Continued

Read More

OrthAlign, Inc. Announces Full Commercial Launch of UniAlign™, the world’s first handheld navigation device for use in Unicompartmental Knee Arthroplasty

Aliso Viejo, CA – March 6, 2017 – OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with precision tools, announced the full commercial launch of UniAlign™, the world’s first handheld navigation device for unicompartmental knee arthroplasty (UKA). UniAlign provides surgeons with OrthAlign’s clinically-proven handheld navigation technology, along with instruments … Continued

Read More

ClearFlow Participates in Clinical Panel Presentations at Critical Care Conference

Washington, DC – September 20, 2016—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the clinical and economic benefits of maintaining chest tube patency following cardiothoracic surgery last Friday at a session sponsored during the Cardiovascular-Thoracic (CVT) Critical Care Conference in Washington DC. Clinical cardiac … Continued

Read More

ClearFlow Opens New Distribution Center to Service European Market

Elsloo, THE NETHERLANDS – September 28, 2016 — ClearFlow, Inc., a medical device company headquartered in Anaheim, California and with a European office in Amsterdam, has announced the opening of its new dedicated European Service Center near Maastricht, the Netherlands. ClearFlow is the maker of the PleuraFlow® Active Clearance Technology® System, which proactively prevents or … Continued

Read More

ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System

Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) … Continued

Read More

ClearFlow Executives Comment on Need for New Protocols

Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have … Continued

Read More

Ablexis Announces Perpetual License of the AlivaMab Mouse to Tri-Institutional Therapeutics Discovery Institute

Ablexis Continues Expansion of List of Licensees of AlivaMab Mouse BURLINGAME, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) — Ablexis, LLC announced today that it has entered into a non-exclusive, perpetual license agreement with the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) in New York City to provide access to the AlivaMab Mouse for antibody drug discovery … Continued

Read More

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. … Continued

Read More